GLP-1 RAs STEP 1 (2021) : Semaglutide 2.4 ./ 14.9% 68 2.4% (Wilding et al., 2021, NEJM) SURMOUNT-1 (2022) : Tirzepatide (GLP-1/GIP dual agonist) 15 ./ 20.9% (Jastreboff et al., 2022, NEJM) GLP-1 HbA1c () 2 (Hypoglycemia) Glucose-dependent LEADER (liraglutide) SUSTAIN-6 (semaglutide) 2024 FDA Semaglutide (Wegovy) FLOW (2024) semaglutide (MASLD/NAFLD) GLP-1 RAs GLP-1
Researchers Study Barriers to GLP-1 Insurance Coverage Regardless of coverage, researchers urge caution for patients seeking alternatives OXFORD, Miss
Addressing Potential Medication Interactions Because semaglutide affects metabolism, doctors must watch for drug interactions
It helps stimulate insulin secretion after meals, but a significant effect observed during its use for diabetes was weight loss, leading to its application in weight management
Reusing needles increases infection risk and dulls the tip, making injections more painful